HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 2, 2016--
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced that company Chief Medical Officer Dr. Larry Altstiel, MD, PhD
will be giving a platform presentation titled “Clinical Support for
Advancement of the RAGE Antagonist Azeliragon into Phase 3 Clinical
Investigation for Mild Alzheimer’s Disease” at the International
Psychogeriatric Association International Congress on Wednesday,
September 7 between 10:00 and 11:30am.
The Phase 2b results of 5mg per day of azeliragon over a period of 18
months showed statistically significant benefit in mild-to-moderate
Alzheimer’s patients (+3.1 points on ADAS-Cog11 standard measure of
cognition) and greater benefit in mild patients (+4.0 points on
ADAS-Cog11), with improvements on secondary endpoints including a
statistically significant reduction in psychiatric adverse events.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160902005083/en/
Source: vTv Therapeutics Inc.
Investors
IR@vtvtherapeutics.com
or
Media
PR@vtvtherapeutics.com
or
vTv
Therapeutics
Nura Strong, 336-841-0300 X164
nstrong@vTvTherapeutics.com
